• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Davis Robert Matthews was granted 3,219 shares, increasing direct ownership by 26% to 15,492 units (SEC Form 4)

    5/19/25 2:55:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Davis Robert Matthews

    (Last) (First) (Middle)
    6601 W BROAD ST

    (Street)
    RICHMOND VA 23230

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ALTRIA GROUP, INC. [ MO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/15/2025 A 3,219(1) A $0 15,492 D
    Common Stock 178 I By wife
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Stock awarded under the 2015 Stock Compensation Plan for Non-Employee Directors.
    Remarks:
    W. Hildebrandt Surgner, Jr. for R. Matt Davis 05/19/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    11/10/2022$38.00Neutral → Sell
    UBS
    6/29/2022$53.00 → $36.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altria Holds 2025 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.02 Per Share

      Altria Group, Inc. (Altria) (NYSE:MO) held our 2025 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer, addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Preliminary Voting Results The preliminary voting results from our shareholders at the Annual Meeting were as follows: elected to a one-year term each of the 11 nominees for our Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025; approved, on an advisory b

      5/15/25 1:30:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria to Host Webcast of 2025 Annual Meeting of Shareholders

      Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast of its 2025 Annual Meeting of Shareholders ("2025 Annual Meeting" or "meeting") on Thursday, May 15, 2025 at 9:00 a.m. Eastern Time. The 2025 Annual Meeting will be held virtually via live webcast. During the meeting, shareholders as of the 2025 Annual Meeting record date (March 25, 2025) will be able to vote their shares electronically and will be able to submit questions during the meeting as time permits. Although shareholders will be able to vote their shares during the meeting, they are encouraged to do so before the meeting using one of the methods described in the 2025 Proxy Statement. If you are not a shareholder

      5/1/25 10:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

      Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

      4/29/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Altria downgraded by Deutsche Bank

      Deutsche Bank downgraded Altria from Buy to Hold

      4/1/25 3:04:54 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Morgan Stanley initiated coverage on Altria with a new price target

      Morgan Stanley initiated coverage of Altria with a rating of Equal-Weight and set a new price target of $54.00

      1/16/25 7:47:52 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria upgraded by BofA Securities with a new price target

      BofA Securities upgraded Altria from Neutral to Buy and set a new price target of $65.00 from $55.00 previously

      12/6/24 7:56:47 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yzaguirre Mario Max was granted 3,219 shares, increasing direct ownership by 25% to 16,252 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      5/19/25 3:06:43 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Strahlman Ellen R was granted 3,219 shares, increasing direct ownership by 16% to 23,087 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      5/19/25 3:05:17 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Stoddart Richard S was granted 3,219 shares (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      5/19/25 3:03:40 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:08:44 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:03:21 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care